Prostate Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Prostate Cancer stocks.

Prostate Cancer Stocks Recent News

Date Stock Title
Apr 25 AMGN Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for
Apr 25 IONS Ionis Publishes 2023 Corporate Responsibility Report
Apr 25 SNY US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
Apr 24 AMGN Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
Apr 24 MYGN Will Myriad Genetics (MYGN) Report Negative Q1 Earnings? What You Should Know
Apr 24 SNY What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Apr 23 SNY Sanofi reportedly lining up banks for consumer products spinoff
Apr 23 SNY Sanofi Asks Banks to Pitch for $20 Billion OTC Spinoff
Apr 23 SNY Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
Apr 23 SNY Sanofi succeeds in late-stage trial for blood disorder candidate
Apr 23 EDAP EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy to be Presented During Plenary Session at the Upcoming 119th American Urological Association (AUA) Annual Meeting
Apr 23 IONS Ionis to hold first quarter 2024 financial results webcast
Apr 23 SNY Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
Apr 22 PROF Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
Apr 22 SNY Sanofi reportedly settles 4K Zantac cases for $100M
Apr 22 SNY Market Chatter: Sanofi to Pay More Than $100 Million to Settle 4,000 Suits Alleging Zantac Causes Cancer
Apr 22 AMGN 10 Best Performing Biotech ETFs in 2024
Apr 21 SNY Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Apr 19 AMGN The Dividend Goldmine: 3 Shining Stocks With Growing Payouts
Apr 18 SNY Sanofi to overhaul US operations of vaccines, cut jobs
Prostate Cancer

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other areas of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. In later stages, it can lead to difficulty urinating, blood in the urine or pain in the pelvis, back, or when urinating. A disease known as benign prostatic hyperplasia may produce similar symptoms. Other late symptoms may include feeling tired due to low levels of red blood cells.Factors that increase the risk of prostate cancer include older age, a family history of the disease, and race. About 99% of cases occur in males over the age of 50. Having a first-degree relative with the disease increases the risk two to threefold. In the United States, it is more common in the African American population than the White American population. Other factors that may be involved include a diet high in processed meat, red meat or milk products or low in certain vegetables. An association with gonorrhea has been found, but a reason for this relationship has not been identified. An increased risk is associated with the BRCA mutations. Prostate cancer is diagnosed by biopsy. Medical imaging may then be done to determine if the cancer has spread to other parts of the body.Prostate cancer screening is controversial. Prostate-specific antigen (PSA) testing increases cancer detection, but it is controversial regarding whether it improves outcomes. Informed decision making is recommended when it comes to screening among those 55 to 69 years old. Testing, if carried out, is more reasonable in those with a longer life expectancy. While 5α-reductase inhibitors appear to decrease low-grade cancer risk, they do not affect high-grade cancer risk and thus are not recommended for prevention. Supplementation with vitamins or minerals does not appear to affect the risk.Many cases are managed with active surveillance or watchful waiting. Other treatments may include a combination of surgery, radiation therapy, hormone therapy or chemotherapy. When it only occurs inside the prostate, it may be curable. In those in whom the disease has spread to the bones, pain medications, bisphosphonates and targeted therapy, among others, may be useful. Outcomes depend on a person's age and other health problems as well as how aggressive and extensive the cancer is. Most men with prostate cancer do not end up dying from the disease. The 5-year survival rate in the United States is 99%. Globally, it is the second most common type of cancer and the fifth leading cause of cancer-related death in men. In 2012, it occurred in 1.1 million men and caused 307,000 deaths. It was the most common cancer in males in 84 countries, occurring more commonly in the developed world. Rates have been increasing in the developing world. Detection increased significantly in the 1980s and 1990s in many areas due to increased PSA testing. Studies of males who died from unrelated causes have found prostate cancer in 30% to 70% of those over age 60.

Browse All Tags